EGFR and non-small cell lung carcinoma: The advent of molecularly targeted small molecule inhibitors, exemplified by epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors (TKIs), has notably improved treatment outcomes for patients diagnosed with non-small cell lung cancer (NSCLC) [1,2,3,4,5].